Skip to main content

Table 4 Relationship between pharmacokinetic parameters of MPA and development of adverse effects

From: Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis

  

n

Dose

Dose/body weight

C0

Cmax

AUC0-12

AUC0-12

/ Dose

AUC0-0.5

(mg)

(mg/kg)

(μg/mL)

(μg/mL)

(μg∙h/mL)

(μg∙h/mL/mg)

(μg∙h/mL)

Gastrointestinal involvement

 + 

10

1500 (1500–1500)

28.3 (25.8–30.9)

1.9 (1.3–3.1)

26.3* (15.4–29.7)

63.4* (53.8–89.4)

0.049 (0.031–0.062)

6.3** (4.2–7.9)

 − 

23

1500 (1500–1875)

227.6 (23.6–35.0)

1.8 (1.2–2.8)

12.3 (8.7–19.7)

45.3 (34.8–68.4)

0.030 (0.024–0.052)

2.9 (1.0–3.7)

Infection

 + 

14

1500 (1500–1875)

28.5 (26.3–33.2)

1.6 (1.2–3.2)

17.0 (10.9–23.5)

49.7 (41.3–77.8)

0.028 (0.024–0.047)

3.3 (2.5–3.9)

 − 

19

1500 (1500–1625)

27.3 (21.9–34.6)

1.9 (1.2–2.6)

12.8 (10.4–27.7)

51.1 (40.8–68.4)

0.036 (0.030–0.061)

3.7 (1.1–6.6)

  1. Values represent the median (IQR). * p < 0.05, **p < 0.01
  2. Gastrointestinal symptoms: diarrhea, vomiting, and epigastric pain
  3. Infections: upper respiratory infection, fever, pharyngitis, bronchitis, oral herpes, herpes zoster, Malassezia, and Aspergillus